Researchers at Johns Hopkins University have published groundbreaking results from a Phase III clinical trial of a novel immunotherapy treatment that achieved a 90% remission rate in patients with advanced-stage solid tumors. The treatment, designated JH-7291, uses engineered T-cells combined with a proprietary checkpoint inhibitor.
The trial, which enrolled 1,200 patients across 15 countries over four years, demonstrated significantly higher efficacy than existing treatments while producing fewer severe side effects. Patients with advanced lung, breast, and colorectal cancers all showed strong response rates.
The FDA has granted the treatment Breakthrough Therapy designation, which could accelerate approval. Analysts estimate the therapy could be available to patients by early 2027, though questions remain about manufacturing scalability and cost, with initial estimates suggesting treatment could exceed $200,000 per patient.
Updated: